Evan is the CEO and co-founder of Genesis. Evan founded Genesis in 2019 to further develop and apply AI and simulation research he conducted in Vijay Pande’s lab at Stanford University. This research included a groundbreaking physics-based ML framework called PotentialNet, which Evan developed to work for challenging and data-poor drug targets. Evan earned his B.S. in applied physics from Yale University and his Ph.D. in computational biophysics from Stanford University. His work has appeared in journals including Science, Nature, ACS Central Science, and the Journal of Medicinal Chemistry. He has been recognized as an honoree in the Forbes 30 Under 30 list for his work, and he has earned recognition for Genesis in the Forbes AI 50 for several consecutive years.

Will has nearly thirty years of healthcare industry experience and leads multiple corporate functions including business development, finance, investor relations, human resources, new product planning and program management. Prior to joining Genesis, Will was Chief Business Officer at Generation Bio where he helped drive corporate strategy initiatives including the company’s Initial Public Offering. Previously he was Chief Business Officer at Ignyta, where he was responsible for commercial strategy and was a key participant in the company’s acquisition by Roche. Earlier in his career he held positions of increasing responsibility at Foundation Medicine, Halozyme and Neurocrine. Will has an MBA from London Business School and a BA from Exeter University

Shifeng brings to Genesis more than two decades of experience in drug discovery across multiple therapeutic areas, which includes a 22-year career at Novartis, where he served as the Head of Discovery Chemistry at the Genomics Institute of the Novartis Research Foundation. There, he led the discovery of FDA-approved drugs ODOMZO®, BRAFTOVI®, and MAYZENT®, as well as numerous other programs across several therapeutic areas. Shifeng comes to Genesis from Odyssey Therapeutics, where he was Executive Vice President and Head of Discovery. He holds a Ph.D. in organic chemistry from New York University.

Aleksandra is an AI leader with over two decades of experience pioneering ML for high-consequence, complex systems, in traditionally ML-resistant domains like robotics, autonomous driving, seismic networks, and satellite ground segments. Her decade in Alphabet includes overseeing foundational model learning research as a Director of Research at Google DeepMind, co-founding Reinforcement Learning in Google Brain, and establishing ML for planning and controls at Waymo. At Sandia National Laboratories, she was PI for adaptive seismic tuning and led satellite launch integrations. Aleksandra earned her Ph.D. in Computer Science (with distinction) from the University of New Mexico, M.S. in Computer Science from the University of Illinois Urbana-Champaign, and B.S. in Mathematics and Computer Science from the University of Belgrade. Having co-authored over 60 publications, her research has been recognized with multiple best paper awards, an IEEE RAS Early Career Award among others, and featured in the New York Times and Forbes.

Steve leads the biology team at Genesis and has extensive cell, molecular and biochemical experience in signaling and cancer biology. Prior to Genesis Steve spent over a decade at Pfizer developing small molecule oncology drugs, including acting as the Research Project Leader for the next generation CDK2/4/6 and CDK2-selective inhibitors. Steve completed his biology Ph.D. at the University of Victoria and then a postdoc on mTOR/S6K signaling with George Thomas at the University of Cincinnati.

Indra leads the medicinal chemistry team at Genesis. Prior to Genesis Indra spent 20+ years in medicinal chemistry at Pfizer working primarily on oncology small molecule programs. At Pfizer, Indra played a leadership role for several programs, including CDK’s, PAK4, EZH2, PRMT5 and STING, all of which produced clinical candidates. He obtained his Ph.D. from UCLA and an NIH postdoctoral fellowship at Harvard University.

Wang leads the company’s finance and accounting teams and oversees all accounting, forecasting, management reporting, and business analytics functions. Prior to joining Genesis, Wang served as Controller at NovaBay Pharmaceuticals, where she was responsible for all accounting matters including SEC reporting, general accounting, and Sarbanes-Oxley compliance. Wang also served as Controller at AltheaDx, and as Assistant Controller at Oldcastle Materials. Wang started her career at Ernst & Young in Atlanta, serving audit clients in a variety of industries. Wang received a Masters of Accounting from UNC Chapel Hill.

Erica has more than 15 years of experience in drug discovery and translational science, having held scientific and leadership roles at the University of Colorado, Pfizer and Takeda.  Most recently Erica was an independent consultant to biotech and pharmaceutical companies. She has a diverse background in DMPK, modeling and simulation, biomarker implementation and in vivo pharmacology.  Erica obtained her Ph.D. in Pharmaceutical Science at the University of Colorado Health Sciences Center and completed her fellowship in Experimental Therapeutics at the University of Colorado Anschutz Medical Campus.

Carl leads business development at Genesis and has over a decade of experience in life sciences. Prior to joining Genesis, Carl served as Head of Corporate Development at BrightInsight, a health tech startup backed by General Catalyst and Insight Partners. He also worked as a Project Leader at the Boston Consulting Group, where he led a variety of engagements for pharmaceutical clients. Carl has a Ph.D. in chemical engineering from UCSB, and MEng & BA degrees from the University of Cambridge.

Géza leads the Immunology & Inflammation team at Genesis Therapeutics. His career in small molecule drug discovery began over two decades ago in Europe. After relocating to San Diego and completing a postdoc at The Scripps Research Institute, he gained valuable experience at Takeda and Johnson & Johnson before transitioning into biotech to contribute to drug discovery at Jecure and later at Vividion Therapeutics – both of which led to successful exits and small molecule candidates advancing to the clinic. Prior to joining Genesis, he served as Executive Director at Odyssey Therapeutics. Géza holds a PhD from Eötvös Loránd University in Budapest, Hungary.

Michael leads computational biophysics at Genesis. Prior to Genesis, he spent seven years at D. E. Shaw Research, where he led early-stage drug discovery programs and developed state-of-the-art molecular simulation and machine learning technologies leveraging the Anton supercomputers. Michael received his Ph.D. from the Physiology, Biophysics, and Systems Biology program at Weill Cornell Medicine, the medical college of Cornell University, and was a member of the faculty there for nearly a decade.

Evan is the CEO and co-founder of Genesis. Evan founded Genesis in 2019 to further develop and apply AI and simulation research he conducted in Vijay Pande’s lab at Stanford University. This research included a groundbreaking physics-based ML framework called PotentialNet, which Evan developed to work for challenging and data-poor drug targets. Evan earned his B.S. in applied physics from Yale University and his Ph.D. in computational biophysics from Stanford University. His work has appeared in journals including Science, Nature, ACS Central Science, and the Journal of Medicinal Chemistry. He has been recognized as an honoree in the Forbes 30 Under 30 list for his work, and he has earned recognition for Genesis in the Forbes AI 50 for several consecutive years.

Dr. Friedman brings decades of experience in biotechnology and drug discovery, having served in senior leadership roles of several notable biotechnology companies, including CEO of Madrigal Pharmaceuticals; CEO of Incyte; President of R&D at DuPont-Merck Pharmaceutical Company; President of DuPont Pharmaceuticals Research Laboratories; and Senior Vice President of Merck Research Laboratories. Dr. Friedman has served as a board member for several publicly held pharmaceutical companies, including Incyte, from 2001 to 2021, and Alexion, from 2017 through its acquisition by AstraZeneca in 2021. He is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation, and received his M.D. from Harvard Medical School.

Kris Jenner is a co-founder and managing member of Rock Springs Capital, a healthcare-focused fund based in Baltimore, MD. Prior to founding Rock Springs in 2013, Kris was a vice president of T. Rowe Price Group, Inc., and T. Rowe Price Associates, Inc. Prior to going to T. Rowe Price, he worked at the Laboratory of Biological Cancer, The Brigham & Women’s Hospital, Harvard Medical School. He earned a B.S. in chemistry, summa cum laude, from the University of Illinois, a D. Phil. from Oxford University as a Marshall Scholar, and an M.D. from the Johns Hopkins University, School of Medicine.

Vijay Pande, PhD, is a General Partner and has been at Andreessen Horowitz since 2014.  He founded and leads a16z Bio + Health, which invests in life sciences and healthcare through four dedicated funds with more than $3 billion under management. Vijay leads the firm’s investments at the cross section of biology and computer science, including applications in computation, machine learning, and artificial intelligence in healthcare; digital therapeutics; diagnostics; and other novel transformative scientific advances that take bio beyond healthcare. He is also an Adjunct Professor of Structural Biology at Stanford University. He currently sits on the boards of Alpine Bio, Apeel Sciences, BioAge, Devoted Health, Freenome, Function Health, Genesis Therapeutics, Inceptive Therapeutics, insitro, Nautilus Biotechnology, Omada Health, Q.bio, and Scribe Therapeutics.

Prior to joining Andreessen Horowitz, Vijay was the Henry Dreyfus Professor of Chemistry and Professor of Structural Biology and of Computer Science at Stanford University, where he led a team of researchers pioneering computational methods and their application to medicine and biology (resulting in over 300 publications and six patents). Vijay was also concurrently the director of the Biophysics program at Stanford, where he led a team of more than 50 faculty members and propelled the program to the top in the country. Vijay also co-founded Globavir Biosciences, and founded the Folding@Home Distributed Computing Project.

Vijay holds a BA in Physics from Princeton University and a PhD in Physics from MIT. He has been awarded the DeLano Prize in Computation, a Guinness World Record for Folding@Home, the American Chemical Society Thomas Kuhn Paradigm Shift Award, and was selected for MIT TR10. In his teens, Vijay was the first employee at video game startup Naughty Dog, maker of Crash Bandicoot and The Last of Us.

Peppi co-founded Inception Sciences as well as Amira Pharmaceuticals. Previously, as a medicinal chemist at Merck he played a key role in the discovery and development of FDA-approved drugs Vioxx®, Arcoxia®, and Singulair®.